Amelioration of inflammatory bowel disease by Bifidobacterium animalis subsp. lactis XLTG11 in combination with mesalazine
2024

Improving Inflammatory Bowel Disease with Probiotics and Medication

Sample size: 60 publication 10 minutes Evidence: high

Author Information

Author(s): Ma Weiwei, Wu Yanan, Lin Xinyue, Yang Liping, Huang Lili

Primary Institution: College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China

Hypothesis

Can Bifidobacterium animalis subsp. lactis XLTG11 combined with mesalazine improve the treatment of inflammatory bowel disease?

Conclusion

The combination of Bifidobacterium animalis subsp. lactis XLTG11 and mesalazine significantly improved symptoms of inflammatory bowel disease in mice.

Supporting Evidence

  • The XLTG11+5-ASA group showed superior recovery compared to the XLTG11-only and 5-ASA-only groups.
  • The combination treatment significantly reduced myeloperoxidase activity and intestinal permeability.
  • The treatment increased levels of beneficial short-chain fatty acids and improved gut microbiota composition.

Takeaway

This study found that a special probiotic combined with a common medicine helped mice with a gut disease feel better.

Methodology

Sixty mice were divided into five groups and treated with different combinations of Bifidobacterium animalis subsp. lactis XLTG11 and mesalazine, followed by assessments of body weight, intestinal permeability, cytokine levels, and microbiota composition.

Potential Biases

Potential funding bias from the National Natural Science Foundation of China and other grants.

Limitations

The study was conducted on mice, and results may not directly translate to humans.

Participant Demographics

BALB/c mice, 60 total, housed in controlled conditions.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.3389/fmicb.2024.1472776

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication